Topics: Research and Development, ALS, Rare Diseases, GoBoldly
From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy’s father inspired her to become a scientist. Years later, his ALS diagnosis made her life’s work personal.
Watch our conversation about the challenges of finding an ALS treatment and the hope we have in research and development. As our payment system evolves, it’s crucial that innovative medicines are accessible and affordable for the patients who need them.
Anne McDonald Pritchett, PhD Anne McDonald Pritchett, Ph.D., is Senior Vice President, Policy and Research, at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing the development of legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, and other issue areas impacting the environment for innovation. In addition to her public policy work, she and her team lead the development of a range of educational and other materials focused on explaining the R&D process, the value of innovation, and the role and contributions of the innovative biopharmaceutical industry.
Topics: Research and Development, ALS, Rare Diseases, GoBoldly
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004